Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors

Nitschke, Ruprecht; Pratt, Charles B.; Harris, Michael B.; Krischer, Jeffrey P.; Vietti, Teresa J.; Grier, Holcombe E.; Kamps, Willem A.; Toledano, Stuart

doi:10.1007/bf00873123

Cited by 3 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Etoposide has shown limited activity when administered as a single agent 27) but may enhance the effect of other drugs such as cyclophosphamide 28 , 29) . When administered as single agents, 5-azacytidine 30) , 5-FU/leucovorin 31) , iproplatin 32 , 33) , ecteinascidin-743 34) , and topotecan 35) seem to be more or less inactive.…”

Section: New or Other Chemotherapeutic Agents?mentioning

confidence: 99%

Osteosarcoma in Korean children and adolescents

Lee¹

2015

Korean J Pediatr

View full text Add to dashboard Cite

Osteosarcoma is the most frequent primary bone tumor. Advances in combination chemotherapy and surgical technique have greatly improved the survival of patients with osteosarcoma. In Korea, improvements in osteosarcoma treatment have been made over the past two decades. The 5-year event-free survival rate of Korean children and adolescents with localized disease is 64.6%, comparable to that of American or European patients. This article provides an overview of current therapies for osteosarcoma in Korea.

show abstract

Section: New or Other Chemotherapeutic Agents?mentioning

confidence: 99%

Osteosarcoma in Korean children and adolescents

Lee¹

2015

Korean J Pediatr

View full text Add to dashboard Cite

show abstract

Osteosarkom

Bielack¹,

Carrle²,

Winkler³

Therapiekonzepte Onkologie

View full text Add to dashboard Cite

The status of platinum anticancer drugs in the clinic and in clinical trials

et al. 2010

View full text Add to dashboard Cite

Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for\ud the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and\ud melanoma. Unfortunately its continued use is greatly limited by severe dose limiting side effects and\ud intrinsic or acquired drug resistance. Over the last 30 years, 23 other platinum-based drugs have entered\ud clinical trials with only two (carboplatin and oxaliplatin) of these gaining international marketing\ud approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual\ud nations. During this time there have been more failures than successes with the development of 14 drugs\ud being halted during clinical trials. Currently there are four drugs in the various phases of clinical trial\ud (satraplatin, picoplatin, LipoplatinTM and ProLindacTM). No new small molecule platinum drug has\ud entered clinical trials since 1999 which is representative of a shift in focus away from drug design and\ud towards drug delivery in the last decade. In this perspective article we update the status of platinum\ud anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued\ud during clinical trials, and discuss the results in the context of where we believe the field will develop over\ud the next decade

show abstract

Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors

Cited by 3 publications

References 3 publications

Osteosarcoma in Korean children and adolescents

Osteosarcoma in Korean children and adolescents

Osteosarkom

The status of platinum anticancer drugs in the clinic and in clinical trials

Contact Info

Product

Resources

About